Article info
PDFCurrent controversy
Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
- Correspondence to Professor Nir Eyal, Center for Population-Level Bioethics, Dept of Philosophy (SAS) and Dept of HBSP (SPH), Rutgers University, New Brunswick, New Jersey, USA; nir.eyal{at}rutgers.edu
Citation
Do coronavirus vaccine challenge trials have a distinctive generalisability problem?
Publication history
- Received November 26, 2020
- Revised March 10, 2021
- Accepted April 20, 2021
- First published June 7, 2021.
Online issue publication
November 16, 2022
Article Versions
- Previous version (16 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Other content recommended for you
- COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement
- Exploring the ethics of tuberculosis human challenge models
- Research ethics and public trust in vaccines: the case of COVID-19 challenge trials
- Comparison of T-cell immune responses to SARS-CoV-2 spike (S) and nucleocapsid (N) protein using an in-house flow-cytometric assay in laboratory employees with and without previously confirmed COVID-19 in South Africa: nationwide cross-sectional study
- T cell immune memory after covid-19 and vaccination
- Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease—streptococcal vaccine development: a national heart, lung and blood institute workshop report
- Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy
- Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination
- Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines
- Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia